Liposomal Market Overview
Product Overview and Scope of Liposomal
Liposomal refers to a delivery system used in pharmaceuticals and supplements. It involves encapsulating active ingredients within lipid (fat) vesicles called liposomes. Liposomes are microscopic structures composed of one or more lipid bilayers, which closely resemble the structure of cell membranes.
The liposomal delivery system has gained popularity due to its ability to improve the absorption and bioavailability of certain substances. By encapsulating the active ingredients within liposomes, it helps protect them from degradation in the digestive system and facilitates their transport across cell membranes.
The lipid bilayers of liposomes are made up of phospholipids, which are natural components found in cell membranes. These phospholipids can vary in composition, allowing for customization of the liposomal properties, such as size, stability, and release characteristics.
Liposomal formulations are commonly used in the pharmaceutical industry to enhance the delivery of drugs. By encapsulating drugs within liposomes, they can be targeted to specific cells or tissues, increasing their effectiveness and reducing potential side effects. Liposomal formulations have been developed for various applications, including cancer treatment, antimicrobial therapy, and gene therapy.
In the field of dietary supplements, liposomal formulations are used to improve the absorption and bioavailability of nutrients and bioactive compounds.
Liposomal Market – Global Industry Analysis
Market Drivers
- The increased demand for targeted drug delivery is a significant driver of the global liposomal market.
Targeted drug delivery systems, including liposomal formulations, offer the potential to enhance the therapeutic efficacy of drugs. By specifically targeting the affected cells or tissues, liposomes can deliver drugs in higher concentrations and for a longer duration, increasing their effectiveness in treating the disease.
Conventional drug delivery methods often lead to off-target effects and systemic toxicity. Targeted drug delivery systems like liposomes can minimize these side effects by delivering drugs directly to the desired site, sparing healthy tissues from unnecessary exposure. This can improve patient safety and tolerability of treatments.
Liposomes can be designed to accumulate preferentially in specific tissues or cells due to their size, surface properties, or specific ligands attached to their surface. This enables targeted drug delivery to sites such as tumors, inflamed tissues, or infection sites, where the drug's action is needed the most.
Targeted drug delivery systems align with the growing trend of personalized medicine. By tailoring the drug delivery approach to individual patients and their specific disease characteristics, liposomal formulations can optimize treatment outcomes and patient responses.
Overall, the increased demand for targeted drug delivery arises from the potential to enhance treatment outcomes, minimize side effects, improve drug stability, and enable personalized and precise medicine. These factors have led to the growing adoption of liposomal formulations in the pharmaceutical industry.
Market Restraint
- High Development and Manufacturing Costs presents significant challenge to the market.
Market Opportunity
- Expansion in Therapeutic Applications offers huge growth potential for the market.
Global Liposomal Revenue by Regions (2018-2023)
Global Liposomal Revenue and Market Share (%) by regions (2018-2023)
Global Liposomal Revenue (USD Billion) by regions (2018-2023)
|
2018 |
2019 |
2020 |
2021 |
2022 |
2025 |
2030 |
CAGR |
|
|
North America |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
|
Europe |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
|
Asia Pacific |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
|
Latin America |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
|
Middle East & Africa |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
|
Total |
XX |
XX |
XX |
XX |
XX |
XX |
8.74 |
8.50% |
Global Liposomal Revenue Market Share (%) by regions in 2022
|
Global Liposomal Revenue Market Share (%) by regions in 2022 |
|
|
|
Source: Cognitive Market Research |
Based on region, North America is dominating the liposomal market in terms of revenue market share throughout the forecast period. This is due to the presence of several key players of the liposomal in this region. In addition, the high prevalence of various chronic diseases coupled with developed healthcare sector expected to drive the liposomal market in the region.
Global Liposomal Revenue by Segment
Global Liposomal Market by Product
- Liposomal Doxorubicin
- Liposomal Amphoteracin B
- Liposomal Paclitaxel
- Others
Global Liposomal Market by Application
- Fungal Infection Therapy
- Cancer Tumor Therapy
- Others
Global Liposomal Market by Technology
- Stealth Liposome Technology
- Non-PEGylated Liposome Technology
- DepoFoam Liposome Technology
- Lysolipid Thermally Sensitive Liposome
Global Liposomal Market by End-user
- Hospitals
- Homecare
- Others
Global Liposomal Manufacturers Profiles/Analysis
Gilead Sciences Inc.
Gilead Sciences Inc. Company Basic Information, and Sales Area
|
|
Item |
Description |
|
|
Company Name |
Gilead Sciences, Inc. |
|
|
Website |
www.gilead.com |
|
|
Established Date |
1987 |
|
|
Headquartered |
United States |
|
|
Market Position/History |
Gilead Sciences, Inc. is founded in 1987. In 1990, AmBisome was approved (in Europe). In 1999, the establishment of European operations NeXstar was acquired by Gilead Sciences, Inc. The company acquired Triangle Pharmaceuticals and Corus, Raylo, and Myogen in 2003 and 2006 respectively. Similar to this, over the course of time, Gilead Sciences, Inc. has been engaging in the acquisition and approval of several brands which makes it a global player. |
|
|
Sales Area |
Worldwide |
|
|
Manufacturing Location |
Worldwide |
|
|
Ticker |
NASDAQ: GILD |
|
|
No. of Employees |
17,000+ |
|
|
Competitors |
Pacira Sun Pharmaceutical Johnson & Johnson Luye Pharma Sigma Tau Ipsen (Onivyde) Teva Pharmaceutical Novartis |
|
|
CEO |
Daniel O'Day |
|
|
Ownership Type |
Public |
|
|
Contact Number |
333 Lakeside Drive, Foster City, CA 94404 Tel: +1 650 574 3000 |
Business Segment/ Overview:
Gilead Sciences, Inc. is a biopharmaceutical business that conducts research to find, develop, and commercialize novel medications in areas of unmet medical need. It strives to enhance the treatment of people suffering from life-threatening diseases worldwide with each new discovery and experimental medication candidate. Gilead's key areas of emphasis are HIV/AIDS, liver disorders, significant respiratory and cardiovascular illnesses, cancer, and inflammation.
Recent Developments:
|
Year |
Latest News |
|
January 2023 |
WHO and Gilead Sciences extend collaborative agreement to enhance access to treatment for visceral leishmaniasis The World Health Organisation (WHO) and Gilead Sciences have signed a new agreement to donate 304,700 vials of AmBisome (liposomal amphotericin B for injection) for the treatment of visceral leishmaniasis in disease-endemic countries, extending their previous agreement until 2025. The new three-year agreement, valued at $11.3 million, also includes financial assistance to enhance increased coverage and access to diagnosis and treatment for populations impacted by visceral leishmaniasis. The product donation will benefit affected populations in high-burden countries such as Bangladesh, Ethiopia, India, Kenya, Nepal, Somalia, South Sudan, Sudan, and Uganda along with expansion to include Eritrea, and Yemen as new recipients to treat severe and complicated cases. |
Business Strategy
Gilead Sciences, Inc. strongly focuses to discover and develop transformational therapies in areas of high unmet medical need. It intends to continue committing significant resources to internal R&D opportunities and external business development activity to drive innovation and growth of the business. Furthermore, Gilead Sciences, Inc. aspires to expand the commercial portfolio and development pipeline across numerous therapeutic areas through acquisitions, in-licensing, and strategic alliances.
